Chirag Shah, MD

Chirag Shah, MD, discusses ongoing clinical trials aiming to minimize surgical intervention in locoregional breast cancer.

Despite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.

Over the past several decades, breast-conserving therapy has emerged as the standard of care in the management of early-stage breast cancer.